アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hope pharmaceuticals - sodium thiosulfate (unii: hx1032v43m) (thiosulfate ion - unii:llt6xv39py) - sodium thiosulfate 250 mg in 1 ml - sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. when the diagnosis of cyanide poisoning is uncertain, the potential risks associated with sodium thiosulfate injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. none risk summary there are no available data on sodium thiosulfate injection use in pregnant women to establish a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. there are risks to the pregnant woman and fetus associated with untreated cyanide poisoning (see clinical considerations). therefore, if a pregnant woman has known or suspected cyanide poisoning, sodium thiosulfate injection for sequential use with sodium nitrite is recommended [see indications and usage (1)] . in published animal studies, no evidence of embryotoxicity or malformations was reported when sodium thiosulfate was administered during organogenesis to pregnant mice, rats, hamsters, or rats at 0.2 to 0.9 times the human daily dose of 12.5 g for cyanide poisoning. the studies did not test doses that were comparable to the human dose for cyanide poisoning (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk cyanide readily crosses the placenta. cyanide poisoning is a medical emergency in pregnancy, which can be fatal for the pregnant woman and fetus if left untreated. life-sustaining therapy should not be withheld due to pregnancy. data animal data: no malformations or evidence of embryo-fetal toxicity were noted when pregnant mice, rats, hamsters, or rabbits were administered oral doses of sodium thiosulfate of up to 550, 400, 400, or 580 mg/kg, respectively during organogenesis (0.2, 0.3, 0.26, and 0.9 times the human dose of 12.5 g/60 kg person for cyanide poisoning based on body surface area). published studies suggest that treatment with sodium thiosulfate ameliorates the teratogenic effects of maternal cyanide poisoning in hamsters. risk summary there are no data on the presence of sodium thiosulfate in human or animal milk, the effects on the breastfed infant, or the effects on milk production. cyanide and thiocyanate (which is formed when sodium thiosulfate combines with cyanide) are present in human milk. because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with sodium thiosulfate injection. there are no data to determine when breastfeeding may be safely restarted following the administration of sodium thiosulfate injection. there are case reports in the medical literature of sodium nitrite in conjunction with sodium thiosulfate being administered to pediatric patients with cyanide poisoning; however, there have been no clinical studies to evaluate the safety or efficacy of sodium thiosulfate in the pediatric population. as for adult patients, dosing recommendations for pediatric patients have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports. sodium thiosulfate is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. sodium thiosulfate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

イスラエル - 英語 - Ministry of Health

rekah pharmaceutical industry ltd, israel - sodium bicarbonate - tablets - sodium bicarbonate 500 mg - sodium bicarbonate - sodium bicarbonate - antacid.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - sodium chloride injection, usp is indicated for parenteral restoration of sodium ion in patients with restricted oral intake.  sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome.  sodium chloride injection may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes. sodium chloride injection is contraindicated in patients with hypernatremia or fluid retention.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - sodium chloride injection, usp, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion.  it is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs.  after available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from sodium chloride injection, usp, 23.4% and diluted for use. sodium chloride injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases.  isotonic sodium chloride injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. the toxic symptoms that follow various

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

general injectables & vaccines, inc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 30 ml - sodium chloride injection, usp, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patents who have special problems of sodium electrolyte intake or excretion. it is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. after available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from sodium chloride injection, usp, 23.4% and diluted for use. sodium chloride injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. isotonic sodium chloride injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. the toxic symptoms that follow various form

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hospira, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, monobasic, monohydrate 276 mg in 1 ml - sodium phosphates injection, usp, 3 mm p/ml is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of sodium (na+ 4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions. sodium phosphate is contraindicated in diseases where high phosphorus or low calcium levels may be encountered, and in patients with hypernatremia.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - sodium oxybate (unii: 7g33012534) (4-hydroxybutanoic acid - unii:30iw36w5b2) - sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy. sodium oxybate oral solution is contraindicated for use in: risk summary there are no adequate data on the developmental risk associated with the use of sodium oxybate in pregnant women. oral administration of sodium oxybate to pregnant rats (150, 350, or 1,000 mg/kg/day) or rabbits (300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity; however, oral administration to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and growth, at a clinically relevant dose [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - sodium oxybate (unii: 7g33012534) (4-hydroxybutanoic acid - unii:30iw36w5b2) - sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy. sodium oxybate oral solution is contraindicated for use in: risk summary there are no adequate data on the developmental risk associated with the use of sodium oxybate in pregnant women. oral administration of sodium oxybate to pregnant rats (150, 350, or 1,000 mg/kg/day) or rabbits (300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity; however, oral administration to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and growth, at a clinically relevant dose [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - disodium methylarsonate = dsma; mcpa as the sodium salt - suspension concentrate - disodium methylarsonate = dsma mineral-arsenic active 220.0 g/l; mcpa as the sodium salt phenoxy acids-mcpa active 70.0 g/l - herbicide - bent lawn or turf | bowling green of bent grass | bowling green of common couch | common couch lawn or turf | golf green of bent - barnyard or water grass | bindy-eye | capeweed | cat's ear or flatweed | chickweed | clover | common cotula or carrot weed | cudweed | dandelion - taraxacum officinale | duckweed | fleabane | mouse-ear chickweed | mullumbimby couch | nutgrass | paspalum | ribwort, ribgrass or lamb's tongue | scarlet or red pimpernel | summer or crab grass | water couch | white clover | annual summer grass | barnyard grass | bindii | bird's eye | bogan flea | calotis hispidula | common chickweed | common dandelion | common duckweed | common plantain | english dandelion | european dandelion | jo-jo | lemna minor | lesser duckweed | mouse-eared chickweed | narrow leaf plantain | onehunga weed | paspalum paspalodes | star burr | swamp couch | sweet summer grass | taraxacum spp. | true dandelion | victorian nutgrass

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hope pharmaceuticals - sodium nitrite (unii: m0kg633d4f) (nitrite ion - unii:j39976l608) - sodium nitrite 30 mg in 1 ml - sodium nitrite injection, an antidote, is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. when the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with sodium nitrite injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. none risk summary life-sustaining therapy should not be withheld. cyanide poisoning is a medical emergency in pregnancy, which can be fatal for the pregnant woman and fetus if left untreated (see clinical considerations). therefore, if a pregnant woman has known or suspected cyanide poisoning, sodium nitrite injection for sequential use with sodium thiosulfate injection is recommended [see indications and usage (1)]. there are no available data on sodium nitrite injection use in pregnant women to establish a drug-associated risk for major birth defects, miscarriage, or adverse maternal